Alterations of serum protein N-glycosylation in two mouse models of chronic liver disease are hepatocyte and not B cell driven

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 300, Issue 5, 2011, Pages

  Blomme, Bram ^a   van Steenkiste, Christophe ^a   Grassi, Paola ^c   Haslam, Stuart M ^c   Dell, Anne ^c   Callewaert, Nico ^b   van Vlierberghe, Hans ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

B cells; CBDL; CCI4; DSA FACE; Glycomics

Indexed keywords

CARBON TETRACHLORIDE; GLYCAN; GLYCOSIDASE; IMMUNOGLOBULIN G; PLASMA PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CHRONIC LIVER DISEASE; COMMON BILE DUCT OBSTRUCTION; CONTROLLED STUDY; GLYCOSYLATION; HISTOPATHOLOGY; LIVER CELL; LIVER FIBROSIS; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METHYLATION; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; WESTERN BLOTTING;

ANIMALS; B-LYMPHOCYTES; BILE DUCTS; BLOOD PROTEINS; BODY WEIGHT; CARBON TETRACHLORIDE POISONING; CHRONIC DISEASE; DRUG-INDUCED LIVER INJURY; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLYCOPROTEINS; GLYCOSYLATION; HEPATOCYTES; IMMUNOGLOBULIN G; LIGATION; LIVER; MALE; METHYLATION; MICE; MICE, 129 STRAIN; ORGAN SIZE; POLYSACCHARIDES; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 79955551474     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00228.2010     Document Type: Article

References (30)

1. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 24: 289-293, 1996.
2. Blomme BA, Van Steenkiste C, Vanhuysse J, Colle I, Callewaert N, Van Vlierberghe H. The impact of elevation of total bilirubin level and etiology of the liver disease on serum N-glycosylation patterns in mice and men. Am J Physiol Gastrointest Liver Physiol 298: G615-G624, 2010.
3. Callewaert N, Van Vlierberghe H, Van Hecke A, Laroy W, Delanghe J, Contreras R. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med 10: 429-434, 2004.
4. Ceroni A, Maass K, Geyer H, Geyer R, Dell A, Haslam SM. Glyco-WorkBench: a tool for the computer-assisted annotation of mass spectra of glycans. J Proteome Res 7: 1650-1659, 2008.
5. Geerts AM, Vanheule E, Praet M, Van Vlierberghe H, De Vos M, Colle I. Comparison of three research models of portal hypertension in mice: macroscopic, histological and portal pressure evaluation. Int J Exp Pathol 89: 251-263, 2008.
6. Gerardy-Schahn R, Oelmann S, Bakker H. Nucleotide sugar transporters: biological and functional aspects. Biochimie 83: 775-782, 2001.
7. Janakat S, Al-Merie H. Optimization of the dose and route of injection, and characterisation of the time course of carbon tetrachloride-induced hepatotoxicity in the rat. J Pharmacol Toxicol Methods 48: 41-44, 2002.
8. Jang-Lee J, North S, Sutton-Smith M, Goldberg D, Panico M, Morris H, Haslam S, Dell A. Glycomic profiling of cells and tissues by mass spectrometry: fingerprinting and sequencing methodologies. Methods Enzymol 415: 59-86, 2006.
9. Jefferis R. Antibody therapeutics: isotype and glycoform selection. Expert Opin Biol Ther 7: 1401-1413, 2007.
10. Kitamura D, Roes J, Kuhn R, Rajewsky K. A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene. Nature 350: 423-426, 1991.
11. Klein A, Carre Y, Louvet A, Michalski JC, Morelle W. Immunoglobulins are the major glycoproteins involved in the modifications of total N-glycome in cirrhotic patients. Proteomics Clin Appl 4: 379-393, 2010.
12. Klein A, Michalski JC, Morelle W. Modifications of human total serum N-glycome during liver fibrosis-cirrhosis, it is all about immunoglobulins? Proteomics Clin Appl 4: 372-378, 2010.
13. Kobata A. The N-linked sugar chains of human immunoglobulin G: their unique pattern, and their functional roles. Biochim Biophys Acta 1780: 472-478, 2008.
14. Koike C, Uddin M, Wildman DE, Gray EA, Trucco M, Starzl TE, Goodman M. Functionally important glycosyltransferase gain and loss during catarrhine primate emergence. Proc Natl Acad Sci USA 104: 559-564, 2007.
15. Kountouras J, Billing BH, Scheuer PJ. Prolonged bile duct obstruction: a new experimental model for cirrhosis in the rat. Br J Exp Pathol 65: 305-311, 1984.
16. Kotz K, Hansler M, Sauer H, Kaltenhauser S, Hantzschel H. Immunoglobulin G galactosylation deficiency determined by isoelectric focusing and lectin affinoblotting in differential diagnosis of rheumatoid arthritis. Electrophoresis 17: 533-534, 1996.
17. Laroy W, Contreras R, Callewaert N. Glycome mapping on DNA sequencing equipment. Nat Protoc 1: 397-405, 2006.
18. Liu XE, Desmyter L, Gao CF, Laroy W, Dewaele S, Vanhooren V, Wang L, Zhuang H, Callewaert N, Libert C, Contreras R, Chen C. N-glycomic changes in hepatocellular carcinoma patients with liver cirrhosis induced by hepatitis B virus. Hepatology 46: 1426-1435, 2007.
19. Mehta A, Block TM. Fucosylated glycoproteins as markers of liver disease. Dis Markers 25: 259-265, 2008.
20. Mizuochi T, Hamako J, Nose M, Titani K. Structural changes in the oligosaccharide chains of IgG in autoimmune MRL/Mp-lpr/lpr mice. J Immunol 145: 1794-1798, 1990.
21. Mizuochi T, Hamako J, Titani K. Structures of the sugar chains of mouse immunoglobulin G. Arch Biochem Biophys 257: 387-394, 1987.
22. Moritoki Y, Zhang W, Tsuneyama K, Yoshida K, Wakabayashi K, Yang GX, Bowlus C, Ridgway WM, Ueno Y, Ansari AA, Coppel RL, Mackay IR, Flavell RA, Gershwin ME, Lian ZX. B cells suppress the inflammatory response in a mouse model of primary biliary cirrhosis. Gastroenterology 136: 1037-1047, 2009.
23. Novobrantseva TI, Majeau GR, Amatucci A, Kogan S, Brenner I, Casola S, Shlomchik MJ, Koteliansky V, Hochman PS, Ibraghimov A. Attenuated liver fibrosis in the absence of B cells. J Clin Invest 115: 3072-3082, 2005.
24. Raju TS, Briggs JB, Borge SM, Jones AJ. Species-specific variation in glycosylation of IgG: evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics. Glycobiology 10: 477-486, 2000.
25. Raju TS. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol 20: 471-478, 2008.
26. Sasai K, Ikeda Y, Fujii T, Tsuda T, Taniguchi N. UDP-GlcNAc concentration is an important factor in the biosynthesis of β1,6-branched oligosaccharides: regulation based on the kinetic properties of N-acetylglucosaminyltransferase V. Glycobiology 12: 119-127, 2002.
27. Tanabe K, Deguchi A, Higashi M, Usuki H, Suzuki Y, Uchimura Y, Kuriyama S, Ikenaka K. Outer arm fucosylation of N-glycans increases in sera of hepatocellular carcinoma patients. Biochem Biophys Res Commun 374: 219-225, 2008.
28. Van Beneden K, Coppieters K, Laroy W, De Keyser F, Hoffman IE, Van den Bosch F, Vander Cruyssen B, Drennan M, Jacques P, Rottiers P, Verbruggen G, Contreras R, Callewaert N, Elewaut D. Reversible changes in serum immunoglobulin galactosylation during the immune response and treatment of inflammatory autoimmune arthritis. Ann Rheum Dis 68: 1360-1365, 2009.
29. Vanderschaeghe D, Laroy W, Sablon E, Halfon P, Van Hecke A, Delanghe J, Callewaert N. GlycoFibroTest is a highly performant liver fibrosis biomarker derived from DNA sequencer-based serum protein glycomics. Mol Cell Proteomics 8: 986-994, 2009.
30. Yang X, Tang J, Rogler C, Stanley P. Reduced hepatocyte proliferation is the basis of retarded liver tumor progression and liver regeneration in mice lacking N-acetylglucosaminyltransferase III. Cancer Res 63: 7753-7759.